Rafivirumab, formerly referred to as CR57, signifies a intriguing antibody aimed at VEGF receptor 2 or VEGFR2. Its evolution from early discovery involved a substantial effort by Curis , subsequent acquisition with BMS . The therapeutic program has featured several trial assessments, primarily focusing on its efficacy in treating various oncologic